PDCD1 and hepatocellular carcinoma: A phase I/II study of the PD-1 inhibitor nivolumab in 262 patients with advanced, HBV and HCV-infected and non-viral infected HCC, demonstrated a RR of 15 to 20% across dose escalation and OS of 15 months on the expansion cohorts (184).